Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Carrie L. Langstraat, MD, a gynecologic oncologist at Mayo Clinic, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Lansgtraat highlighted findings from a retrospective study in Ohio. The study was able to demonstrate that patients with endometrial cancers who had para-aortic lymph node involvement in addition to pelvic node involvement had worse survival compared with those who had early pelvic nodal involvement.
According to Langstraat, these data are marginal, but there is a decrease in survival for patients with para-aortic lymph node involvement.
<< View more resources and information regarding gynecologic cancers
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More